Home   |   Contact

Call For Abstract

Untitled Document
The Scientific Committee invites authors to submit their abstracts for consideration and inclusion in the programme. 

Abstract Online Submission Opens: 18 May 2015
Abstract submission deadline:  14 February 2016
Abstract evaluation deadline: 28 February 2016

Note: Please note that only ELECTRONIC submission will be accepted. Faxed or mailed abstracts will not be reviewed.


  • Abstracts must be submitted in English. A “blind” selection process will be used. No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
  • The material in the abstract must be original and not previously published.
  • The title should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title.
  • The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. Each section (Introduction & Objectives, Materials & Methods, Results, and Conclusions) should be inserted in the individually labelled boxes.
  • You can click on the relevant icons to insert tables, pictures or specific characters.
  • Structure your abstract using the following subheadings:
    • Introduction & Objectives: A sentence describing the purpose of the study
    • Materials & Methods: Describe your selection of observations or experimental subjects precisely
    • Results: Describe your results in a logical sequence
    • Conclusions: Emphasise new and important aspects of the study and conclusions that are drawn from them
  • Failure to comply with the following requirements will lead to automatic rejection of the submission:
    • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
    • Use generic names. Commercial drug names may not be used. Drugs should be referred to by the active substance or pharmacological designation.
    • No mention of pharmaceutical company names should be included in the abstract.
  • The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:
    • Is the content interesting, informative, novel or important?
    • Are the methods valid, the results relevant and the conclusions justified by the data?
    • Are the data presented with clarity and with appropriate structure?
    • Is the text written according to proper English grammar and syntactic style?
  • The authors have to specify if they wish the submission to presented as:
    • Poster presentation only
    • Oral presentation only (that is, if rejection of the abstract, no communication!)
    • Poster or oral presentation


Submission of an abstract implies that it has been approved by all listed authors.

The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation.

Accepted abstracts will be published on the official abstract CD ROM, which will be distributed at the Congress in the delegate bags. The abstracts may also be published on the EADV website. Submission of an abstract constitutes your consent to publication (e.g. Congress website, programmes, other promotional material, etc...)

Abstracts will be published as submitted. Errors will not be amended by the organisers.


  1. Acne and Related Disorders,
  2. Adverse Drug Reactions,
  3. Allergology and Immunology
  4. Angiology, Haemangiomas, Vascular Malformations, Vasculitis
  5. Atopic Dermatitis/Eczema
  6. Autoimmune Bullous Diseases
  7. Autoimmune Connective Tissue Disorders
  8. Biologics, Immunotherapy, Molecularly Targeted Therapy
  9. Contact and Occupational Dermatitis
  10. Corrective, Aesthetic and Cosmetic Dermatology
  11. Cutaneous Oncology
  12. Dermatological Practice Management
  13. Dermatological Surgery
  14. Dermatology and Internal Medicine, including Skin Manifestations of Systemic Diseases
  15. Dermatopathology
  16. Dermoscopy
  17. Diagnostic Procedures
  18. Economics in Dermatology, Ethics in Dermatology
  19. Epidemiology
  20. Genetics
  21. Hair Disorders/Diseases
  22. Infectious Diseases, Parasitic Diseases, Infestations
  23. Inflammatory Skin Diseases
  24. Inherited Skin Diseases
  25. Lasers  
  26. Miscellaneous
  27. Nail Disorders/Diseases  
  28. Oral Mucosa and other Skin-adjacent Mucous Membranes
  29. Paediatric Dermatology
  30. Pharmacology and Skin-related Toxicology, Phlebology   
  31. Photobiology and Photoallergy
  32. Phototherapy, Photodynamic Therapy
  33. Pigmentary Diseases  
  34. Pregnancy-related Dermatoses   
  35. Pruritus
  36. Psoriasis   
  37. Psychodermatology
  38. Quality of Life
  39. Sexually Transmitted Infections, HIV/AIDS     
  40. Systemic Treatment
  41. Topical Therapy
  42. Tropical Dermatovenereology
  43. Urticaria, Angioedema
  44. Wounds, Chronic Wounds, Wound Healing, Ulcers 
Copyright 2015 Mersin √úniversitesi. All Rights Reserved
LookUs & Online Makale